L. Pierre, M. Philippe, M. Pharmacie-galénique-alain, M. Chimie-thérapeutique-patrick, M. Jean-louis et al., Chimie physique générale, Biochimie, Biologie moléculaire

B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle, and B. Microbiologie-environnementale-michel, Chimie thérapeutique, Chimie thérapeutique François BONNEAUX

B. Ariane, B. Cédric, C. Igor, C. Chimie-analytique-joël, D. Sébastien et al., Hématologie -Génie Biologique, Chimie thérapeutique François DUPUIS..............................................Pharmacologie Raphaël DUVAL ..............................................Microbiologie clinique

F. Adil, F. Biophysique-acoustique-luc, G. Caroline, .. Di-stasio, G. Expertise-biopharmacologique-stéphane et al., Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique ASSISTANTS HOSPITALO-UNIVERSITAIRES, Biochimie et Biologie

.. Droite-d-'étalonnage-et-contrôles, 41 Préparation des échantillons de sang 42 2.1.5. Validation de la méthode selon les normes COFRAC

.. Discussion, 69 4.1.1. Aspects techniques, Conclusion et perspectives, p.72

J. Goldman and J. Melo, Chronic Myeloid Leukemia ??? Advances in Biology and New Approaches to Treatment, New England Journal of Medicine, vol.349, issue.15, pp.1451-64, 2003.
DOI : 10.1056/NEJMra020777

M. Ichimaru, M. Tomonaga, T. Amenomori, and T. Matsuo, Atomic bomb and leukemia, J

P. Nowell and D. Hungerford, Chromosome studies on normal and leukemic human leukocytes, J Natl Cancer Inst, vol.25, pp.85-109, 1960.

J. Rowley, A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining, Nature, vol.71, issue.5405, pp.290-293, 1973.
DOI : 10.7326/0003-4819-72-2-175

M. Cohen, G. Williams, J. Johnson, J. Duan, J. Gobburu et al., Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia

N. Singh, L. Kumar, R. Meena, and T. Velpandian, Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders, European Journal of Clinical Pharmacology, vol.101, issue.6, pp.545-554, 2009.
DOI : 10.1007/s00228-009-0621-z

A. Awidi, A. Ayed, N. Bsoul, A. Magablah, R. Mefleh et al., Relationship of serum imatinib trough level and response in CML patients: Long term follow-up, Leukemia Research, vol.34, issue.12, pp.1573-1578, 2010.
DOI : 10.1016/j.leukres.2010.07.014

G. Wei, S. Rafiyath, D. Liu, D. Gibbons, S. Pricl et al., First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm Reappraisal of histogenesis, ):26225. 11. Mazur MT, Clark HB. Gastric stromal tumors, pp.47507-47526, 1983.

J. Paral, I. Slaninka, H. Kalabova, and D. Hadzi-nikolov, Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options

G. Monges, S. Bisot-locard, J. Blay, A. Bouvier, M. Urbieta et al., The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists, Bull Cancer, vol.97, issue.3, pp.16-22, 2010.

M. Nakahara, K. Isozaki, S. Hirota, J. Miyagawa, N. Hase-sawada et al., A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumor, Gastroenterology, vol.114
DOI : 10.1016/S0016-5085(98)82666-8

H. Joensuu and S. Dimitrijevic, Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours, Annals of Medicine, vol.20, issue.7, pp.451-456, 2001.
DOI : 10.1056/NEJM200104053441404

G. Demetri, A. Van-oosterom, C. Garrett, M. Blackstein, M. Shah et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, The Lancet, vol.368, issue.9544, pp.1329-1367, 2006.
DOI : 10.1016/S0140-6736(06)69446-4

I. Collins and P. Workman, New approaches to molecular cancer therapeutics, Nature Chemical Biology, vol.2, issue.12, pp.689-700, 2006.
DOI : 10.1016/j.cbpa.2004.04.015

I. Wistuba, J. Gelovani, J. Jacoby, S. Davis, and R. Herbst, Methodological and practical challenges for personalized cancer therapies, Nature Reviews Clinical Oncology, vol.40, issue.3, pp.135-176, 2011.
DOI : 10.1053/j.semnuclmed.2010.05.002

G. Lurje and H. Lenz, EGFR Signaling and Drug Discovery, Oncology, vol.77, issue.6, pp.400-410, 2009.
DOI : 10.1159/000279388

C. Langer, Roles of EGFR and KRAS Mutations in the Treatment Of Patients With

A. Lievre, J. Bachet, L. Corre, D. Boige, V. Landi et al., Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3997, 2006.
DOI : 10.1158/0008-5472.CAN-06-0191

X. An, A. Tiwari, Y. Sun, P. Ding, C. Ashby et al., BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review, Leukemia Research, vol.34, issue.10, pp.1255-68, 2010.
DOI : 10.1016/j.leukres.2010.04.016

S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint et al., Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, vol.109, issue.8, pp.3496-3505, 2007.
DOI : 10.1182/blood-2006-07-036012

R. Larson, B. Druker, F. Guilhot, O. Brien, S. Riviere et al., Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, vol.111, issue.8, pp.4022-4030, 2008.
DOI : 10.1182/blood-2007-10-116475

F. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet et al., Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, The Lancet Oncology, vol.11, issue.11, pp.1029-1064, 2010.
DOI : 10.1016/S1470-2045(10)70233-3

B. Peng, C. Dutreix, G. Mehring, M. Hayes, M. Ben-am et al., Absolute Bioavailability of Imatinib (Glivec??) Orally versus Intravenous Infusion, The Journal of Clinical Pharmacology, vol.24, issue.Suppl. 1, pp.158-62, 2004.
DOI : 10.1007/BF02353475

N. Van-erp, H. Gelderblom, H. Guchelaar, N. Widmer, M. Duchosal et al., Clinical pharmacokinetics of tyrosine kinase inhibitors Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib, Population Br J Clin Pharmacol. Cancer Treat Rev. Blood, vol.6235117, issue.3288, pp.97-112692, 2006.

B. Druker, C. Sawyers, H. Kantarjian, D. Resta, S. Reese et al., Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome, New England Journal of Medicine, vol.344, issue.14
DOI : 10.1056/NEJM200104053441402

M. Holtz, M. Slovak, F. Zhang, C. Sawyers, S. Forman et al., Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation, Blood, vol.99, issue.10, pp.3792-800, 2002.
DOI : 10.1182/blood.V99.10.3792

E. Jabbour, M. Deininger, and A. Hochhaus, Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia, Leukemia, vol.114, issue.2, pp.201-211, 2011.
DOI : 10.1182/blood-2008-12-196543

H. Kantarjian, N. Shah, A. Hochhaus, J. Cortes, S. Shah et al., Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2260-70, 2010.
DOI : 10.1056/NEJMoa1002315

L. Christopher, D. Cui, C. Wu, R. Luo, J. Manning et al., Metabolism and Disposition of Dasatinib after Oral Administration to Humans, Drug Metabolism and Disposition, vol.36, issue.7, pp.1357-64, 2008.
DOI : 10.1124/dmd.107.018267

X. Li, Y. He, C. Ruiz, M. Koenig, and M. Cameron, Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways, Drug Metabolism and Disposition, vol.37, issue.6, pp.1242-50, 2009.
DOI : 10.1124/dmd.108.025932

G. Saglio, D. Kim, S. Issaragrisil, P. Le-coutre, G. Etienne et al., Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2251-2260, 2010.
DOI : 10.1056/NEJMoa0912614

J. Trent and M. Molimard, Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors, Seminars in Oncology, vol.38, issue.1, pp.28-33, 2011.
DOI : 10.1053/j.seminoncol.2011.01.014

C. Tanaka, O. Yin, V. Sethuraman, T. Smith, X. Wang et al., Clinical Pharmacokinetics of the BCR???ABL Tyrosine Kinase Inhibitor Nilotinib, Clinical Pharmacology & Therapeutics, vol.106, issue.2, pp.197-203, 2009.
DOI : 10.5414/CPP38532

A. Tefferi and L. Letendre, Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia, American Journal of Hematology, vol.86, issue.7, pp.610-611, 2011.
DOI : 10.1002/ajh.22051

URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.22051/pdf

F. Mahon and M. Molimard, Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia, Leukemia Research, vol.33, issue.8, pp.1147-1155, 2009.
DOI : 10.1016/j.leukres.2009.02.030

Y. Wang, Y. Chia, J. Nedelman, H. Schran, F. Mahon et al., A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times, Therapeutic Drug Monitoring, vol.31, issue.5, pp.579-84, 2009.
DOI : 10.1097/FTD.0b013e3181b2c8cf

N. Takahashi, H. Wakita, M. Miura, S. Scott, K. Nishii et al., Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia, Clinical Pharmacology & Therapeutics, vol.49, issue.6, pp.809-822, 2010.
DOI : 10.1016/S1570-0232(01)00611-0

Q. Li, C. Chen, Z. Chen, H. Wang, Y. Wu et al., Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients, Acta Pharmacologica Sinica, vol.46, issue.8
DOI : 10.1007/s00277-008-0589-2

A. Ibrahim, L. Eliasson, J. Apperley, D. Milojkovic, M. Bua et al., Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, Blood, vol.117, issue.14, pp.3733-3739, 2011.
DOI : 10.1182/blood-2010-10-309807

I. Judson, P. Ma, B. Peng, J. Verweij, A. Racine et al., Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group, Cancer Chemotherapy and Pharmacology, vol.364, issue.4, pp.379-86, 2005.
DOI : 10.1007/s00280-004-0876-0

G. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova et al., Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?, J Clin Oncol. Cancer Treat Rev, vol.2737, issue.4, pp.3141-7291, 2009.

C. Yoo, M. Ryu, B. Ryoo, M. Beck, H. Chang et al., Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability, Invest New Drugs. Br J Cancer, vol.98, issue.10, pp.1633-1673, 2008.

O. Roth, O. Spreux-varoquaux, S. Bouchet, P. Rousselot, S. Castaigne et al., Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS, Clinica Chimica Acta, vol.411, issue.3-4, pp.3-4140, 2010.
DOI : 10.1016/j.cca.2009.10.007

R. Bakhtiar, L. Khemani, M. Hayes, T. Bedman, and F. Tse, Quantification of the anti-leukemia drug STI571 (Gleevec???) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, vol.28, issue.6, pp.1183-94, 2002.
DOI : 10.1016/S0731-7085(02)00080-8

T. Velpandian, R. Mathur, N. Agarwal, B. Arora, L. Kumar et al., Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples, Journal of Chromatography B, vol.804, issue.2, pp.431-435, 2004.
DOI : 10.1016/j.jchromb.2004.01.032

D. Ivanovic, M. Medenica, B. Jancic, and A. Malenovic, Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec?? capsules, Journal of Chromatography B, vol.800, issue.1-2
DOI : 10.1016/j.jchromb.2003.10.018

E. Allan, T. Holyoake, A. Craig, and H. Jorgensen, Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells, Leukemia, vol.25, issue.6, pp.985-94, 2011.
DOI : 10.1182/blood-2008-06-164582

N. Velev, J. Cortes, R. Champlin, D. Jones, G. Rondon et al., Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I, Cancer, vol.26, issue.15S, pp.3631-3638, 2010.
DOI : 10.1002/cncr.25092

M. Ballas and A. Chachoua, Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC, OncoTargets and Therapy, vol.4, pp.43-58, 2011.
DOI : 10.2147/OTT.S18155

L. Faivre, C. Gomo, O. Mir, F. Taieb, A. Schoemann-thomas et al., A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma, Journal of Chromatography B, vol.879, issue.23, pp.2345-50, 2011.
DOI : 10.1016/j.jchromb.2011.06.026

C. Geyer, J. Forster, D. Lindquist, S. Chan, C. Romieu et al., Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer, New England Journal of Medicine, vol.355, issue.26, pp.2733-2776, 2006.
DOI : 10.1056/NEJMoa064320

F. Bai, B. Freeman, C. Fraga, M. Fouladi, and C. Stewart, Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC???ESI-MS/MS), Journal of Chromatography B, vol.831, issue.1-2, pp.169-75, 2006.
DOI : 10.1016/j.jchromb.2005.11.044

S. Roche, G. Mcmahon, M. Clynes, O. Connor, and R. , Development of a high-performance liquid chromatographic???mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib, Journal of Chromatography B, vol.877, issue.31, pp.3982-90, 2009.
DOI : 10.1016/j.jchromb.2009.10.008